Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Finished Goods (2023 - 2025)

Historic Finished Goods for China SXT Pharmaceuticals (SXTC) over the last 3 years, with Q1 2025 value amounting to $448668.0.

  • China SXT Pharmaceuticals' Finished Goods fell 1896.65% to $448668.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $448668.0, marking a year-over-year decrease of 1896.65%. This contributed to the annual value of $448668.0 for FY2025, which is 1896.65% down from last year.
  • As of Q1 2025, China SXT Pharmaceuticals' Finished Goods stood at $448668.0, which was down 1896.65% from $553682.0 recorded in Q1 2024.
  • China SXT Pharmaceuticals' Finished Goods' 5-year high stood at $553682.0 during Q1 2024, with a 5-year trough of $446866.0 in Q1 2023.
  • For the 3-year period, China SXT Pharmaceuticals' Finished Goods averaged around $483072.0, with its median value being $448668.0 (2025).
  • Its Finished Goods has fluctuated over the past 5 years, first soared by 2390.34% in 2024, then tumbled by 1896.65% in 2025.
  • Quarter analysis of 3 years shows China SXT Pharmaceuticals' Finished Goods stood at $446866.0 in 2023, then rose by 23.9% to $553682.0 in 2024, then dropped by 18.97% to $448668.0 in 2025.
  • Its last three reported values are $448668.0 in Q1 2025, $553682.0 for Q1 2024, and $446866.0 during Q1 2023.